NYZL1 Pep-LNP

Name: NYZL1 Pep-LNP
SKU: TDLD-0825-LD96
Rating: 5 (1 reviews)

Datasheet

Cat. No.: TDLD-0825-LD96

NYZL1 Pep-LNP

NYZL1 Pep-LNP is a state-of-the-art peptide-functionalized lipid nanoparticle (LNP), designed for efficient targeted delivery of therapeutic cargoes such as siRNA, mRNA, DNA, small molecule drugs, and RNA-guided gene editing systems. Engineered with the NYZL1 peptide, which exhibits significant specific binding to bladder cancer tissues and cells, this LNP offers enhanced specificity for these targets. Our LNP is prepared using DSPE-PEG-NYZL1 and a variety of optional lipid formulations including DLin-MC3-DMA, LP-01, ALC-0315, SM102, and others. These formulations are carefully selected to ensure the LNP has uniform particle size, high encapsulation efficiency, stability, and targeted delivery. Applications of NYZL1 Pep-LNP include targeted therapy for bladder cancer, developing NYZL1-specific imaging agents for early detection or monitoring, and studying the biology of bladder cancer cells and potential drug delivery mechanisms. Please note that this product is intended for research purposes only.

SPECIFIC INQUIRY

Payload:

Modification:

Lipid Formulation:

Dye:

Concentration:

Quantity:

Inquiry

For Research Use Only. Not for Diagnostic or Treatment Applications.

Payload Type	mRNA
Payload	Empty; EGFP mRNA; Firefly Luciferase mRNA; mCherry mRNA; GFP mRNA; OVA mRNA; EPO mRNA; Renilla Luciferase mRNA; Gaussia Luciferase mRNA; Beta-galactosidase mRNA; Cre mRNA; mOrange mRNA; tdTomato mRNA; EYFP mRNA
Capping	Cap 1
Modification	Unmodified; N1-methyl-pseudouridine; 5-methoxyuridine

Module Type	Peptide
Targeting Module	NYZL1 Peptide

Target	Bladder
Lipid Formulation	DLin-MC3-DMA; LP-01; ALC-0315; SM102
Dye	Unlabeled; DiR; DiD; DiO; DiI
Application	Control; Targeted Delivery; Gene Therapy
Concentration	0.1 mg/mL; 0.2 mg/mL; Other (Please Specify)

Size	65-120 nm
PDI	< 0.2
Zeta	± 20.0 mV
Encapsulate Efficiency	>90%

Storage

Store at 2-8°C